Roche - Latest News [Page 1]

Scientist wins national award for cancer research

Saturday, 25 August 2018, 12:17 pm | Roche

University of Otago, Christchurch scientist Dr Andrew Das has won the 2018 NZSO (NZ Society of Oncologists) Roche NZ Translational Cancer Research Fellowship to learn techniques and bioinformatic analyses that will further his work as part of a research ... More >>

Cancer patients gain in Roche’s new multi-medicine agreement

Monday, 5 December 2016, 12:46 pm | Roche

Cancer patients are among those who will benefit from an innovative multi-medicine funding agreement between Pharmac and Roche Products (NZ), announced today. More than 2,000 New Zealand patients, most with life-threatening illnesses, are expected ... More >>

Targeted therapies for patients with advanced melanoma

Wednesday, 9 March 2016, 3:40 pm | Roche

March 9, 2016: Targeted therapies called BRAF inhibitors may offer patients with BRAF V600 mutation-positive advanced melanoma the possibility of longer survival. However, PHARMAC has so far declined to fund them in New Zealand. More >>

Setting the record straight on Herceptin

Monday, 14 December 2015, 11:04 am | Roche

Roche Products NZ dismisses Health Minister Jonathan Coleman’s statement on TV3’s Paul Henry show on Friday, December 11 suggesting that a nine-week course of Herceptin® (trastuzumab) is “just as good as a 52-week” course. Medsafe has not approved ... More >>

More Effective Treatment is Available for Women

Tuesday, 7 October 2014, 4:20 pm | Roche

International study confirms a more effective treatment is available for women with advanced HER2-positive breast cancer More >>

Daily capsule for patients with skin cancer

Wednesday, 23 April 2014, 11:47 am | Roche

Erivedge® (vismodegib), a new medicine that has been shown to help patients with a disfiguring and potentially life-threatening form of skin cancer, is now registered for use in New Zealand More >>

Tarceva Funded First Line for Non-Small Cell Lung Cancer

Thursday, 9 January 2014, 9:39 am | Roche

New Zealanders with a specific type of advanced Non-Small Cell Lung Cancer (NSLC) can now receive funded first line treatment with Tarceva, an anti-cancer medicine from Roche Products. More >>

Two new treatments for breast cancer registered in NZ

Monday, 14 October 2013, 11:10 am | Roche

Two new treatments for advanced HER2-positive breast cancer registered in New Zealand First line treatment PERJETA® and second line treatment KADCYLA® extend and improve the quality of life of patients with advanced HER2-positive breast cancer 14 October ... More >>

Roche NZ welcomes Herceptin duration trial results

Tuesday, 2 October 2012, 10:36 am | Roche

Roche Products (New Zealand) Limited welcomes the results of two studies, PHARE and HERA, which explore different treatment durations of Herceptin when used together with chemotherapy in early-stage HER2-positive breast cancer. [1,2] The studies were ... More >>

Leukaemia patients to benefit as treatment

Thursday, 28 July 2011, 1:33 pm | Roche

New Zealanders with chronic lymphocytic leukaemia (CLL), an incurable form of white blood cell cancer, can now receive funded treatment with MabThera® (rituximab) a leading-edge biotherapy. From 1 August MabThera will be funded for use in combination ... More >>

Roche welcomes Health Select Committee report

Wednesday, 8 June 2011, 12:07 pm | Roche

Roche Products New Zealand welcomes today’s release of the Health Select Committee’s report as a milestone opportunity for New Zealand to become recognised as a world leader in clinical research. The report soundly documents the steps that need to ... More >>

Roche sponsors summer student in arthritis research project

Wednesday, 19 January 2011, 11:43 am | Roche

The Wellington Regional Rheumatology Trust has organised a summer studentship through sponsorship by pharmaceutical company Roche. The project will see a research student review treatment outcomes for patients with arthritis who have been treated with ... More >>

Hundreds could benefit as treatment registered

Monday, 18 May 2009, 1:54 pm | Roche

Widened access to a leading-edge biotherapy has given hope to hundreds of New Zealanders diagnosed with chronic lymphocytic leukaemia (CLL), a stubbornly incurable form of white blood cell cancer. Internationally, CLL is the most common type of leukaemia ... More >>

Roche: Tamiflu fact sheet

Wednesday, 29 April 2009, 1:17 pm | Roche

Tamiflu is an antiviral medicine. It is NOT a vaccine.1 It belongs to a group of medicines called neuraminidase inhibitors. These medicines attack the influenza virus and stop it spreading further inside your body.1 More >>

New funding could help avoid health ‘time bomb’

Tuesday, 31 March 2009, 2:39 pm | Roche

Health experts believe that new access to Pegasys® (peginterferon alfa-2a (40KD)), an effective antiviral treatment for two diseases, chronic hepatitis B and C, today announced by PHARMAC, will save thousands of lives and hundreds of millions of taxpayer ... More >>

Roche welcomes decision to fund Herceptin

Thursday, 11 December 2008, 11:06 am | Roche

Roche Products (New Zealand) Limited says it has worked productively with the government, the Ministry of Health and PHARMAC in order to supply Herceptin to New Zealand women with early HER2 positive breast cancer. More >>

Roche welcomes 52 week Herceptin funding

Wednesday, 10 December 2008, 11:18 am | Roche

Roche Products (New Zealand) Limited says it has worked productively with the government, the Ministry of Health and PHARMAC in order to supply Herceptin to New Zealand women with early HER2 positive breast cancer. More >>

New data supports case for funding MabThera®(

Monday, 10 November 2008, 2:05 pm | Roche

New data presented at the American College of Rheumatology’s annual meeting in San Francisco is good news for New Zealanders suffering from moderate to severe Rheumatoid Arthritis (RA), who have failed to respond to the most commonly prescribed biologic ... More >>

Herceptin decision continues to disappoint

Thursday, 7 August 2008, 4:18 pm | Roche

Roche Products (NZ) Ltd is very disappointed that New Zealand women with early HER2 positive breast cancer will continue to miss out on the internationally accepted 52 weeks' treatment with Herceptin(r) (trastuzumab). More >>

Judge orders review of Herceptin decision

Thursday, 3 April 2008, 3:40 pm | Roche

Roche Products (New Zealand) Limited welcomes Justice Gendall’s directive to set aside PHARMAC’s decision not to fund 52 weeks of Herceptin® for the treatment of early HER2 positive breast cancer. Svend Petersen, managing director of Roche, ... More >>

 

 

InfoPages Links

 
 

LATEST HEADLINES

  • PARLIAMENT
  • POLITICS
  • REGIONAL